NEW YORK, NY / ACCESSWIRE / June 17, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Bloom Energy Corporation (NYSE: BE)
Class Period: on behalf of all persons who purchased or otherwise acquired Bloom Energy common stock pursuant or traceable to Bloom Energy's July 2018 IPO.
Lead Plaintiff Deadline: July 29, 2019
The complaint alleges that Bloom Energy's Registration Statement was materially misleading as it failed to disclose known events and trends that were severely affecting the Company's business and that made investment in Bloom Energy significantly riskier than presented in the Registration Statement. In particular, the Registration Statement failed to disclose that the Company was experiencing material construction delays. These construction delays would cause system deployments (or "acceptances" as Defendants referred to them) to fall significantly below even the low end of the Company's previously announced guidance.
While the Registration Statement purported to warn of risks that "may arise," which could materially affect the Company, in actuality these material negative events were already occurring. As a result, the representations and purported risk disclosures were false and misleading because, by the time of the IPO, construction delays had already impacted or would soon impact Bloom Energy's ability to deliver acceptances in line with its guidance.
Get additional information about the BE lawsuit: http://www.kleinstocklaw.com/pslra-1/bloom-energy-corporation-loss-submission-form?id=1969&from=1
Intersect ENT, Inc. (NASDAQGM: XENT)
Class Period: August 1, 2018 to May 6, 2019
Lead Plaintiff Deadline: July 15, 2019
According to the complaint, Intersect ENT, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the XENT lawsuit: http://www.kleinstocklaw.com/pslra-1/intersect-ent-inc-loss-submission-form?id=1969&from=1
Heron Therapeutics, Inc. (NASDAQ: HRTX)
Class Period: October 31, 2018 to April 30, 2019
Lead Plaintiff Deadline: August 5, 2019
During the class period, Heron Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (iii) as a result, Heron's public statements were materially false and misleading at all relevant times.
Get additional information about the HRTX lawsuit: http://www.kleinstocklaw.com/pslra-1/heron-therapeutics-inc-loss-submission-form?id=1969&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/548985/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BE-XENT-and-HRTX
